Items tagged with Drug-resistant TB
The Union reinforces commitment to beating AMR as part of global event (post)
The Union announced a series of commitments to combat antimicrobial resistance (AMR) at a conference, in Berlin on 12 and 13 October 2017, organised by Wellcome in partnership with the UK, Ghanaian and Thai governments and the UN Foundation.
Drug-resistant TB cases on rise in India (post)
A study found over 40% of 45,076 patients, in 75 selected studies for review, suspected for resistance to any first-line anti-TB drugs, tested positive in the last 20 years.
WHO to review its interim guidance on the use of delamanid in the treatment of multidrug-resistant TB following the release of Phase III clinical trial results (post)
The World Health Organization (WHO) has started preparations for a rapid review of its interim guidance on the use of delamanid in the treatment of patients with multidrug-resistant tuberculosis (MDR-TB). This follows the release of the phase III randomised control trial results by Otsuka Pharmaceutical at the 48th Union World Conference on Lung Health on 13 October.
Exploring the threat of MDR-TB in the United States (post)
MDR-TB remains relatively rare in the United States. The most recent MDR-TB data, from 2015, include 88 cases, representing about 1% of persons with TB disease. Eighty-five percent were foreign-born persons, and nearly 82% were individuals without a history of TB disease. These statistics emphasize how global control will undoubtedly affect progress toward national TB elimination.
Russian Federation: TB treatments yield promising results in the Chechen Republic (post)
The first new drugs to be developed in 50 years were the last chance for some people with extensively drug-resistant tuberculosis (XDR-TB) in the Chechen Republic of the Russian Federation. In 2015, MSF’s Maria Borshova spoke to patients who had just started their new two-year-long treatments. She recently met them again.
Joint statement on STREAM Stage 1 MDR-TB clinical trial results (post)
Partners In Health (PIH), Interactive Research and Development (IRD) and the Zero TB Initiative (ZTBI) welcome the release of the interim results from the STREAM Stage 1 clinical trial. This is the first clinical trial of a new treatment regimen for multidrug-resistant tuberculosis (MDR-TB), and we congratulate the investigators for successfully conducting it. Unfortunately, we have noticed much confusion about the results of this clinical trial, both in the lay press and in the countries in which we work.
New TB drug making its way to India and Russia (post)
TOKYO -- With tuberculosis killing 1.67 million people every year, Otsuka Pharmaceutical is expediting deliveries of a new drug called Delamanid to India and other developing countries that are desperate for a cure.
Nigeria: Institute wants more TB treatment centres (post)
Institute of Human Virology, Nigeria has appealed to federal, state and local governments to provide more treatment centres for the management of drug resistant tuberculosis.
New TB mutations could transform tests for drug resistance (post)
The emergence of resistance to drugs used to treat the airborne disease tuberculosis (TB) is one of the most urgent health crises facing mankind. Already the world’s number one killer from an infectious disease with 1.67 million deaths in 2016, resistance to anti-tuberculosis drugs is making TB more difficult to cure.
Superbugs: first independent comparison of pharma companies’ efforts to address drug-resistant infections (post)
The Benchmark compares how a cross-section of the pharmaceutical industry is responding to the threat from drug-resistant infections. It measures the 30 most active players in antimicrobial development and production and includes multinational pharmaceutical companies, biotechnology firms and manufacturers of generic medicines.
Page 47 of 117 · Total posts: 0
←First 46 47 48 Last→